Pillar Biosciences Expands Automated NGS Cancer Workflow
NATICK, MASSACHUSETTS, AND RENO, NEVADA, Aug 27, 2026 Pillar Biosciences, Inc. and Hamilton Company have announced the validation and...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NATICK, MASSACHUSETTS, AND RENO, NEVADA, Aug 27, 2026 Pillar Biosciences, Inc. and Hamilton Company have announced the validation and...
Guilford, Connecticut, August 20, 2026 Hyperfine announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s...
Wilmington, Massachusetts, August 20, 2026 Charles River Laboratories International and Medigen Vaccine Biologics Corp. (MVC) have entered into a...
HOUSTON & LAKE FOREST, Calif., July 16, 2026 Plus Therapeutics and Genomic Testing Cooperative (GTC) announced a strategic collaboration...
NASHIK, India, May 21, 2026 Datar Cancer Genetics (DCG) has achieved a major milestone in precision oncology after receiving...
